Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs iShares TIPS Bond ETF (TIP) Price & Performance

AbbVie IncTrade
iShares TIPS Bond ETFTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs iShares TIPS Bond ETF — how do they compare? AbbVie Inc trades at $249.52 (market cap $438.19B), while iShares TIPS Bond ETF trades at $106.95. The key difference: AbbVie Inc pays a 2.79% dividend while iShares TIPS Bond ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares TIPS Bond ETF nearer its low. Which is the better fit depends on your goals.

ABBVTIP
Market Cap
$438.19B
Sector
HealthFixed Income
52-Week High
$263.58$112.20
52-Week Low
$197.38$106.86
Enterprise Value
$502.45B
Dividend Yield
2.79%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $249.94, up 1.59% with bullish technical signals and strong analyst support. The company demonstrates solid revenue growth to $61.16B in 2025, though net margins have compressed to 6.9%. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $3.65 surpassing estimates. Technical indicators show bullish momentum with the current price near resistance at $249, while RSI suggests potential oversold conditions at lower timeframes.

AbbVie presents a compelling investment case with 71% analyst buy ratings and a $281.33 price target offering 12.6% upside. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, though patent cliffs in the 2030s and regulatory risks require monitoring. The company's dividend growth streak and robust pipeline support long-term value, but investors should weigh execution risks against current valuation multiples.

iShares TIPS Bond ETF

TIP trades at $107.08 with minimal daily movement (+0.2%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators are neutral. The stock faces headwinds from broader market concerns about inflation and Federal Reserve policy. Recent dividend distributions provide some shareholder return, but key financial ratios remain undisclosed, limiting fundamental visibility.

Outlook remains cautious due to bearish technicals and macroeconomic uncertainty. Investment opportunity hinges on inflation trends and Fed policy clarity, while risks include prolonged bond market volatility and energy price impacts. Wall Street sentiment appears mixed with technical weakness offset by dividend stability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About iShares TIPS Bond ETF

TIP is the flagship ETF for U.S. Treasury Inflation-Protected Securities (TIPS). It tracks an index of government bonds whose principal value adjusts based on the Consumer Price Index (CPI), providing a direct hedge against rising inflation.

Read more on TIP